• 1
    Smallwood RA, Berlin RG, Castagnoli N, Festen HPM, Hawkey CJ, Lam SK, Langman MJS, et al. Safety of acid-suppressing drugs. Dig Dis Sci 1995; 40: 63S80S.
  • 2
    Wilde MI, McTavish D. Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders. Drugs 1994; 48: 91132.
  • 3
    Lamberts R, Creutzfeldt W, Strüber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrin cell growth, and gastritis. Gastroenterology 1993; 104: 13561370.
  • 4
    Jensen RT, Fraker DL. Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma. JAMA 1994; 271: 14291435.
  • 5
    Metz DC, Strader DB, Orbuch M, Koviack PD, Feigenbaum KM, Jensen RT. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther 1993; 7: 597610.
  • 6
    Bayerdorffer E, Miehlke S, Marines GA, Sommer A, Hochter W, Weingart J, Heldwein W, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infections in patients with duodenal ulcers. Gastroenterology 1995; 108: 14121417.
  • 7
    Andersson T, Andrén K, Cederberg C, Lagerström PO, Lundborg P, Skånberg I. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol 1990; 29: 557563.
  • 8
    Andersson T, Regårdh C-G, Lou Y-C, Zhang Y, Dahl M-L, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2: 2531.
  • 9
    Regårdh C-G, Andersson T, Lagerström Lundborg P, Skånberg I. The pharmacokinetics of omeprazole in humans—a study of single intravenous and oral doses. Ther Drug Monit 1990; 12: 163172.
  • 10
    Sohn D-R, Kobayashi K, Chiba K, Lee K-H, Shin S-G, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an oriental population. J Pharm Exp Ther 1992; 262: 11951202.
  • 11
    Vinayek R, Amantea MA, Maton PN, Frucht H, Gardner JD, Jensen RT. Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome. Gastroenterology 1991; 101: 138147.
  • 12
    Ching MS, Mihaly GW, Angus PW, Morgan DJ, Devenish-Meares S, Yeomans ND, Smallwood RA. Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer. Br J Clin Pharmacol 1991; 31: 166170.
  • 13
    Howden CW, Meredith PA, Forrest JAH, Reid JL. Oral pharmacokinetics of omeprazole. Eur J Clin Pharmacol 1984; 26: 641643.
  • 14
    Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, Meyer UA, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36: 521530.
  • 15
    Andersson T, Miners JO, Veronese ME, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 1994; 37: 597604.
  • 16
    Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T. Oxidative metabolism of omeprazole in human liver microsomes: Cosegregation with S-mephenytoin 4′-hydroxylation. J Pharm Exp Ther 1993; 266: 5259.
  • 17
    Rodvold KA, Piscitelly SC. New oral macrolide and fluoroquinolone antibiotics: an overview of pharmacokinetics, interactions, and safety. Clin Infect Dis 1993; 17(suppl 1): S192S199.
  • 18
    Chang M, Tybring G, Dahl M-L, Gotharson E, Sagar M, Seensalu R, Bertilsson L. Interphenotype differences in disposition and effect on gastrin levels of omeprazole—suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995; 39: 511518.
  • 19
    Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. In: KalowW, ed. Pharmacogenetics of drug metabolism. New York: Pergamon, 1992: 657685.
  • 20
    Brockmöller J, Rost KL, Gross D, Schenkel A, Roots I. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron 4/exon 5 G [RIGHTWARDS ARROW] A-splice site mutation. Pharmacogenetics 1995; 5: 8088.
  • 21
    Rost KL, Brosicke H, Brockmoller J, Scheffler M, Helge H, Roots I. Increase of cytochrome P450IA2 activity by omeprazole: Evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1992; 52: 170180.
  • 22
    Rost KL, Brösicke H, Heinemeyer G, Roots I. Specific and dose dependent enzyme induction by omeprazole in human beings. Hepatology 1994; 20: 12041212.
  • 23
    Lagerström PO, Persson BA. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatography 1984; 309: 347356.
  • 24
    DeMorais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 1541915422.
  • 25
    Rowland M, Tozer TN. Clinical pharmacokinetics: Concepts and applications. 2nd ed. Philadelphia, London: Lea & Febiger, 1989.
  • 26
    Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, et al. Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 1995; 47: 410418.
  • 27
    Andersson T, Miners JO, Veronese ME, Birkett DJ. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 1994; 38: 131137.
  • 28
    Brockmöller J, Roots I. Assessment of liver metabolic function—clinical implications. Clin Pharmacokinet 1994; 27: 216248.
  • 29
    Rost KL, Brockmöller J, Esdorn F, Roots I. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. J Hepatol 1995; 23: 268277.
  • 30
    Reichenspurner H, Meiser BM, Muschiol F, Nollert G, Uberfuhr P, Markewitz A, Wagner F, et al. The influence of gastrointestinal agents on resorption and metabolism of cyclosporine after heart transplantation: experimental and clinical results. J Heart Lung Transplant 1993; 12: 987992.
  • 31
    Parkinson A, Hurwitz A. Omeprazole and the induction of human cytochrome P-450: a response to concerns about potential adverse effects. Gastroenterology 1991; 100: 11571164.
  • 32
    Federal Health Office (Germany), Berlin. Omeprazol und Sehstörungen. Bundesgesundheitsblatt 1993; 36: 293.
  • 33
    Nixon PF, Diefenbach RJ, Duggleby RG. Inhibition of transketolase and pyruvate decarboxylase by omeprazole. Biochem Pharmacol 1992; 44: 177179.
  • 34
    Brown RD. The proton channel blocking agent omeprazole is an inhibitor of the thiamin shuttle. J Theor Biol 1990; 143: 565573.